KevinMD July 30, 2024
Michael Kirsch, MD

Have you ever heard of a drug called Ozempic? Just kidding. As we all know, this medicine and numerous related drugs are the rage. It is classified as a GLP-1 drug. The percentage of my patients who are taking these drugs is steadily rising. Of course, initially, Ozempic’s purpose was in diabetic management. Once it was discovered that weight loss was a “side-effect,” a new therapeutic mission was discovered. Indeed, public demand to use this medicine off-label for weight loss has risen sharply. Currently, there are two GLP-1 agonist medicines that the FDA (Food and Drug Administration) has approved for obesity treatment. I can promise you that pharmaceutical R & D on similar and next-generation weight loss pharmaceuticals is supercharged....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider
208 million Americans are classified as obese or overweight, according to new study on 132 data sources
The Evidence for Gratitude and Health, 2024 Giving Thanks
How 3 Health Systems Are Scaling Hybrid & Home-Based Models
277 million patients' data drives Epic's research findings
Growing gulf in US life expectancy deepened by COVID-19 pandemic

Share This Article